FATE THERAPEUTICS (F6T BE) stock market data APIs
€0.9363
0(0%)
as of July 15, 2025
Try our APIs with
free plan!
FATE THERAPEUTICS Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for F6T.BE.
Prev. Close
0.9363
Open
0.9363
High
0.9363
Low
0.9363
52 wk Range
0.5826-4.968
Market Cap
4 367 M
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get FATE THERAPEUTICS data using free add-ons & libraries
Get FATE THERAPEUTICS Fundamental Data
FATE THERAPEUTICS Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
FATE THERAPEUTICS News
New
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares si...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline...
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?
A month has gone by since the last earnings report for Fate Therapeutics (FATE). Shares have added about 61.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue l...
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
Fate Therapeutics, Inc. All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
